OpenLB
Open Library of Bioscience
Advanced Search
BioMed research international
2022;2022 7841219.

Caerin 1 Peptides, the Potential Jack-of-All-Trades for the Multiple Antibiotic-Resistant Bacterial Infection Treatment and Cancer Immunotherapy.

Liyin Xiao, Xiaodan Yang, Junjie Li, Pingping Zhang, Shuxian Tang, Dongmin Cao, Shu Chen, Hejie Li, Wei Zhang, Guoqiang Chen, Guoying Ni, Tianfang Wang, Xiaosong Liu
Author Information
  1. Liyin Xiao: The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong 510080, China. ORCID
  2. Xiaodan Yang: The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong 510080, China.
  3. Junjie Li: The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong 510080, China.
  4. Pingping Zhang: Cancer Research Institute, First People's Hospital of Foshan, Foshan, Guangdong 528000, China.
  5. Shuxian Tang: Cancer Research Institute, First People's Hospital of Foshan, Foshan, Guangdong 528000, China.
  6. Dongmin Cao: Cancer Research Institute, First People's Hospital of Foshan, Foshan, Guangdong 528000, China. ORCID
  7. Shu Chen: Cancer Research Institute, First People's Hospital of Foshan, Foshan, Guangdong 528000, China.
  8. Hejie Li: Genecology Research Centre, University of the Sunshine Coast, Maroochydore DC, QLD 4558, Australia.
  9. Wei Zhang: The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong 510080, China.
  10. Guoqiang Chen: Cancer Research Institute, First People's Hospital of Foshan, Foshan, Guangdong 528000, China.
  11. Guoying Ni: The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong 510080, China. ORCID
  12. Tianfang Wang: Genecology Research Centre, University of the Sunshine Coast, Maroochydore DC, QLD 4558, Australia. ORCID
  13. Xiaosong Liu: The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong 510080, China. ORCID
PMID: 35445137 DOI: 10.1155/2022/7841219

Abstract

Antibiotic resistance-related bacterial infections and cancers become huge challenges in human health in the 21 century. A number of naturally derived antimicrobial peptides possess multiple functions in host defense, including anti-infective and anticancer activities. One of which is known as the caerin 1 family peptides. The microbicidal properties of these peptides have been long discussed. The recent studies also established the usage of two members in this family, caerin 1.1 and caerin 1.9, in antimultiple antibiotic-resistant bacteria species. It is increasingly evident that caerin 1.1 and caerin 1.9 also contain additional activities in the suppression of tumor. In this review, we briefly outline the therapeutic potentials and possible mechanism of action of caerin 1.1 and 1.9 in the treatment of multiple antibiotic-resistant bacterial infection and cancer immunotherapy.

References

  1. Zool Res. 2019 Mar 18;40(2):94-101 [PMID: 30127328]
  2. Molecules. 2017 Dec 13;22(12): [PMID: 29236056]
  3. EMBO Mol Med. 2014 May 06;6(6):708-20 [PMID: 24803000]
  4. Int J Mol Sci. 2019 Sep 25;20(19): [PMID: 31557917]
  5. Drug Resist Updat. 2012 Feb-Apr;15(1-2):90-7 [PMID: 22387162]
  6. Front Immunol. 2019 Feb 05;10:128 [PMID: 30804938]
  7. Eur Biophys J. 2011 Apr;40(4):545-53 [PMID: 21267557]
  8. N Engl J Med. 2009 Jan 29;360(5):439-43 [PMID: 19179312]
  9. Cell Immunol. 2016 Feb;300:9-17 [PMID: 26607604]
  10. Biochemistry. 2008 Aug 19;47(33):8557-65 [PMID: 18652483]
  11. Molecules. 2020 Nov 25;25(23): [PMID: 33255849]
  12. Eur J Biochem. 1997 Jul 15;247(2):545-57 [PMID: 9266696]
  13. Int J Cancer. 2008 Apr 15;122(8):1810-9 [PMID: 18074354]
  14. Annu Rev Immunol. 1995;13:61-92 [PMID: 7612236]
  15. Microbiol Spectr. 2021 Sep 3;9(1):e0005121 [PMID: 34259550]
  16. Peptides. 2012 Sep;37(1):174-88 [PMID: 22771617]
  17. Ann Nucl Med. 2021 Jul;35(7):811-822 [PMID: 33948902]
  18. Bioact Mater. 2016 Sep 16;1(2):109-121 [PMID: 29744399]
  19. Hell J Nucl Med. 2018 May-Aug;21(2):115-120 [PMID: 30006645]
  20. N Engl J Med. 2009 Nov 5;361(19):1838-47 [PMID: 19890126]
  21. Sci Transl Med. 2011 Aug 10;3(95):95ra73 [PMID: 21832238]
  22. Immunobiology. 2016 Nov;221(11):1259-65 [PMID: 27377709]
  23. Biomolecules. 2018 Aug 22;8(3): [PMID: 30135402]
  24. PLoS One. 2019 Mar 21;14(3):e0213813 [PMID: 30897137]
  25. Cell Mol Life Sci. 2005 Apr;62(7-8):784-90 [PMID: 15868403]
  26. Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):16-27 [PMID: 26667886]
  27. J Exp Med. 2008 Mar 17;205(3):533-41 [PMID: 18332180]
  28. JAMA. 2013 Oct 23;310(16):1661-3 [PMID: 24150445]
  29. Mol Cell. 2020 Jun 18;78(6):1019-1033 [PMID: 32559423]
  30. J Med Chem. 2018 Dec 13;61(23):10709-10723 [PMID: 30427189]
  31. Lancet. 2013 May 11;381(9878):1606-9 [PMID: 23489756]
  32. Front Cell Dev Biol. 2020 Jul 31;8:676 [PMID: 32850805]
  33. P T. 2015 May;40(5):344-52 [PMID: 25987823]
  34. Viruses. 2018 Sep 18;10(9): [PMID: 30231560]
  35. Biochim Biophys Acta. 2014 Sep;1838(9):2205-15 [PMID: 24593995]
  36. CA Cancer J Clin. 2021 May;71(3):209-249 [PMID: 33538338]
  37. Cancer Immunol Immunother. 2016 May;65(5):563-73 [PMID: 26980480]
  38. Am J Hematol. 2019 May;94(S1):S3-S9 [PMID: 30680780]
  39. J Mol Med (Berl). 2007 Apr;85(4):317-29 [PMID: 17216206]
  40. J Intern Med. 2003 Sep;254(3):197-215 [PMID: 12930229]
  41. J Virol. 2005 Sep;79(18):11598-606 [PMID: 16140737]
  42. Peptides. 2001 Oct;22(10):1629-41 [PMID: 11587791]
  43. Am J Transl Res. 2020 Jan 15;12(1):191-202 [PMID: 32051748]
  44. BMC Complement Altern Med. 2019 Jul 6;19(1):163 [PMID: 31277636]
  45. Biochemistry. 2004 Feb 3;43(4):937-44 [PMID: 14744137]
  46. Drug Resist Updat. 2011 Apr;14(2):68-9 [PMID: 21444235]
  47. Curr Med Chem. 2006;13(16):1859-76 [PMID: 16842198]
  48. Peptides. 2015 Sep;71:296-303 [PMID: 26026377]
  49. Technol Cancer Res Treat. 2014 Apr;13(2):177-94 [PMID: 23919392]
  50. Biochimie. 2014 Jun;101:83-92 [PMID: 24412102]
  51. Peptides. 2004 Jun;25(6):1035-54 [PMID: 15203252]
  52. BMC Microbiol. 2019 Mar 8;19(1):54 [PMID: 30849936]
  53. J Immunol Res. 2019 Sep 8;2019:3979352 [PMID: 31583256]
  54. Cancer Chemother Pharmacol. 2000;46 Suppl:S13-7 [PMID: 10950141]
  55. Biochim Biophys Acta. 2008 Feb;1778(2):357-75 [PMID: 18078805]
  56. J Pept Res. 1998 Feb;51(2):121-6 [PMID: 9516047]
  57. JAMA Netw Open. 2019 May 3;2(5):e192535 [PMID: 31050774]
  58. J Immunother. 2017 Feb/Mar;40(2):62-70 [PMID: 28166181]
  59. Biopolymers. 1998;47(6):435-50 [PMID: 10333736]
  60. Lancet Oncol. 2012 Jun;13(6):607-15 [PMID: 22575588]
  61. Front Microbiol. 2013 Mar 12;4:47 [PMID: 23487476]
  62. Chem Phys Lipids. 2003 Jan;122(1-2):107-20 [PMID: 12598042]
  63. Eur J Biochem. 2003 Mar;270(6):1141-53 [PMID: 12631273]
  64. EMBO Rep. 2008 Jul;9 Suppl 1:S13-7 [PMID: 18578017]
  65. Biochemistry. 2012 Dec 21;51(51):10229-35 [PMID: 23194027]
  66. Nature. 2008 Jul 24;454(7203):436-44 [PMID: 18650914]
  67. J Immunol Res. 2015;2015:761820 [PMID: 26568964]
  68. Front Cell Infect Microbiol. 2019 Apr 30;9:128 [PMID: 31114762]
  69. Antibiotics (Basel). 2020 Sep 30;9(10): [PMID: 33008028]
  70. Clin Infect Dis. 2009 Jan 1;48(1):1-12 [PMID: 19035777]
  71. Lancet Oncol. 2016 Nov;17(11):1497-1508 [PMID: 27745820]
  72. Nature. 2016 Jan 21;529(7586):336-43 [PMID: 26791724]
  73. Cell Mol Life Sci. 2011 Jul;68(13):2161-76 [PMID: 21573784]
  74. Future Microbiol. 2021 Mar;16:221-227 [PMID: 33646013]
  75. Front Immunol. 2017 Oct 13;8:1320 [PMID: 29081781]
  76. J Biomed Sci. 2016 Nov 04;23(1):75 [PMID: 27809842]
  77. Eur J Biochem. 2000 Sep;267(17):5330-41 [PMID: 10951191]
  78. Peptides. 2014 Jul;57:67-77 [PMID: 24793775]
  79. P T. 2015 Apr;40(4):277-83 [PMID: 25859123]
  80. Nat Rev Cancer. 2012 Mar 22;12(4):252-64 [PMID: 22437870]
  81. Biochim Biophys Acta. 2016 Dec;1858(12):2959-2964 [PMID: 27639521]
  82. BMC Public Health. 2020 Feb 27;20(1):274 [PMID: 32106837]
  83. Front Cell Infect Microbiol. 2016 Dec 27;6:194 [PMID: 28083516]
  84. Pharmacol Rev. 2003 Mar;55(1):27-55 [PMID: 12615953]
  85. Oncol Rep. 2002 Mar-Apr;9(2):267-76 [PMID: 11836591]
  86. JAMA Netw Open. 2020 Jun 1;3(6):e208759 [PMID: 32589231]
  87. BMC Womens Health. 2019 Jan 7;19(1):3 [PMID: 30616555]
  88. Biochim Biophys Acta. 2013 Aug;1828(8):1863-72 [PMID: 23506683]
  89. Int J Cancer. 2006 Jun 15;118(12):3030-44 [PMID: 16404738]
  90. Cancer Lett. 2008 Nov 18;271(1):47-55 [PMID: 18617323]
  91. CA Cancer J Clin. 2018 Nov;68(6):394-424 [PMID: 30207593]
  92. Clin Transl Immunology. 2021 Aug 17;10(8):e1335 [PMID: 34429969]
  93. Science. 2018 Mar 23;359(6382):1350-1355 [PMID: 29567705]
  94. Nature. 2002 Jan 24;415(6870):389-95 [PMID: 11807545]
  95. Biomed Res Int. 2018 May 13;2018:7382351 [PMID: 29862288]
  96. Clin Infect Dis. 2008 Jan 15;46(2):155-64 [PMID: 18171244]
  97. Biochim Biophys Acta. 2009 Aug;1788(8):1630-8 [PMID: 19013126]
  98. Nat Rev Immunol. 2018 Jan;18(1):46-61 [PMID: 29063907]
  99. Fish Shellfish Immunol. 2020 Mar;98:720-727 [PMID: 31730928]
  100. J Biol Chem. 2015 Aug 7;290(32):19853-62 [PMID: 26100634]

MeSH Term

Amphibian Proteins
Anti-Bacterial Agents
Anti-Infective Agents
Antimicrobial Cationic Peptides
Bacteria
Bacterial Infections
Humans
Immunotherapy
Neoplasms

Chemicals

Amphibian Proteins
Anti-Bacterial Agents
Anti-Infective Agents
Antimicrobial Cationic Peptides
Journal Article Review

Word Cloud

Created with Highcharts 10.0.01caerinpeptides9bacterialmultipleactivitiesfamilyalsoantibiotic-resistantAntibioticresistance-relatedinfectionscancersbecomehugechallengeshumanhealth21centurynumbernaturallyderivedantimicrobialpossessfunctionshostdefenseincludinganti-infectiveanticancerOneknownmicrobicidalpropertieslongdiscussedrecentstudiesestablishedusagetwomembersantimultiplebacteriaspeciesincreasinglyevidentcontainadditionalsuppressiontumorreviewbrieflyoutlinetherapeuticpotentialspossiblemechanismactiontreatmentinfectioncancerimmunotherapyCaerinPeptidesPotentialJack-of-All-TradesMultipleAntibiotic-ResistantBacterialInfectionTreatmentCancerImmunotherapy

Similar Articles

Cited By